- cafead Apr 30, 2024 at 06:42: PM
via NRx Pharmaceuticals’ investigational antidepressant has failed to reach statistical significance in reducing depression severity in a phase 2/3 trial, though the biotech is pressing forward to a registrational study with the belief that the candidate could eventually become a “paradigm-changing blockbuster drug.”
article source
article source